Effect of alemtuzumab or basiliximab induction therapy on graft function and survival of kidneys from donors after cardiac death.

Podobne zapisy

• Results of a Large Randomized Controlled Trial of Alemtuzumab-Versus Basiliximab-Based Induction Therapy in Kidney Transplantation
  od: Haynes, R, i wsp.
  Wydane: (2014)
• Results of a Large Randomized Controlled Trial of Alemtuzumab-Versus Basiliximab-Based Induction Therapy in Kidney Transplantation
  od: Haynes, R, i wsp.
  Wydane: (2014)
• Impact of monoclonal antibody based-induction therapy on postoperative graft function and survival of kidneys from non-heart-beating donors.
  od: Plata-Munoz, J, i wsp.
  Wydane: (2007)
• The deceased donor score system in kidney transplants from deceased donors after cardiac death.
  od: Plata-Munoz, J, i wsp.
  Wydane: (2010)
• Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.
  od: Haynes, R, i wsp.
  Wydane: (2014)